Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 3/20 | 0.50 |
| ▸ | KDM1A | O60341 | 12/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SELL | P14151 | 2/20 | 0.42 |
| ▸ | SELP | P16109 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | FUT4 | P22083 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168972 | 1.00 | RECQL (0.50) | RECQLKDM1AKDM4ELMNATDP1 | |
| SCHEMBL18717467 | 1.00 | RECQL (0.50) | RECQLKDM1AKDM4ELMNATDP1 | |
| Hydrochloric Acid SCHEMBL4170165 | 0.98 | RECQL (0.48) | RECQLKDM1AKDM4ELMNATDP1 | |
| SCHEMBL31716495 | 0.81 | KDM1A (0.46) | RECQLKDM1ALMNAGAAL3MBTL1 | |
| SCHEMBL8121974 | 0.78 | TTR (0.48) | RECQLKDM1AALDH1A1HPGDMAPK1 | |
| SCHEMBL12433083 | 0.76 | KDM1A (0.65) | RECQLKDM1AKDM4EMAPTCA12 | |
| SCHEMBL1338635 | 0.76 | LMNA (0.44) | RECQLKDM1AKDM4ELMNAALDH1A1 | |
| SCHEMBL3237528 | 0.76 | TTR (0.46) | RECQLKDM1ALMNATDP1ALDH1A1 | |
| SCHEMBL1338633 | 0.76 | LMNA (0.44) | RECQLKDM1AKDM4ELMNAALDH1A1 | |
| SCHEMBL3237533 | 0.76 | TTR (0.46) | RECQLKDM1ALMNATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4593859-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | Eresina, LLC (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2024073011-A1 | TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024073013-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | claimed |
| CN-122055367-A | 5-Oxo-4, 5-dihydroimidazo [1,5-a ] quinazoline compounds as PI3K [ alpha ] inhibitors | 皮卡维森治疗学股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3870566-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-8932617-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | RECQL 513/4885KDM1A 2112/4885KDM4E 3319/4885 |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | CCNA1, CDK4, CCNO | RECQL 716/4885KDM1A 1180/4885KDM4E 2159/4885 |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | RECQL 3078/4885KDM1A 3674/4885KDM4E 2774/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | RECQL 1167/4885KDM1A 2620/4885KDM4E 2468/4885 |
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | RECQL 593/4885KDM1A 1447/4885KDM4E 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.